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Abstract
Background: Clinicians draw on instructional approaches when training patients
with anaphylaxis to use adrenaline autoinjectors, but patient use is poor.
Psychological barriers to these behaviours exist but are not considered routinely
when training patients to use autoinjectors. Health Psychology principles suggest
exploring these factors with patients could improve their autoinjector use.
Objective: To evaluate the impact of a 90‐minute workshop training clinicians
in strategies and techniques for exploring and responding to psychological
barriers to autoinjector use with patients. Attendees’ knowledge, confidence
and likelihood of using the strategies were expected to improve.
Methods: Impact was evaluated using a longitudinal mixed‐method design.
Twenty‐nine clinicians (general and specialist nurses, general practitioners, and
pharmacists) supporting patients with anaphylaxis in UK hospitals and general
practice attended. Self‐rated knowledge, confidence, and likelihood of using the
strategies taught were evaluated online 1 week before, 1 to 3, and 6 to 8 weeks
after the workshop. Clinicians were invited for telephone interview after
attending to explore qualitatively the workshop impact.
Results: χ2 analyses were significant in most cases (P< .05), with sustained
(6‐8 weeks) improvements in knowledge, confidence, and likelihood of using
the strategies taught. Thematic analysis of interview data showed the workshop
enhanced attendees’ knowledge of the care pathway, understanding of patient’s
experience of anaphylaxis as psychological not purely physical, and altered their
communication with this and other patient groups. However, interviewees
perceived lack of time and organisational factors as barriers to using the
strategies and techniques taught in clinical contexts.
Conclusion: Training clinicians in psychologically informed strategies produce
sustained improvements in their confidence and knowledge around patient
autoinjector education, and their likelihood of using strategies in clinical practice.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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the original work is properly cited.
Clinical Relevance: Exploring psychological barriers should be part of training
patients with anaphylaxis in autoinjector use.
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1 | INTRODUCTION
Anaphylaxis is a severe, potentially life‐threatening
generalised or systemic hypersensitivity reaction.1(p.835)
International prevalence rates show increasing numbers
of children, adolescents, and adults in Europe and the
United States are being diagnosed with anaphylaxis.2-10
However, diagnosis is difficult and anaphylaxis fatalities
are probably underreported.11 United Kingdom hospital
admission data show a population prevalence of
7 per 100 000, a 615% increase from 1992‐2012.2 Although
a relatively “rare” condition, clinical features of anaphy-
laxis suggest that prevalence could exceed recorded
rates.11,12 This, with the known psychological, social,
and economic costs to anaphylaxis patients and those
supporting them, make effective management of
anaphylaxis a research priority.13-16
Long‐term management of anaphylaxis involves
educating patients in self‐care behaviours to enable
prevention (avoidance of known anaphylaxis triggers),
and effective treatment (adherence to a self‐management
plan and training to deploy adrenaline with an
autoinjector [AAI]).14,17 In the event of anaphylaxis,
early and appropriate intervention with an AAI is the
“first line” treatment against patient death.3,11,18,19
Effective use of AAIs requires patient adherence to these
behaviours: ensuring the AAI prescription is up to date;
carrying an up to date AAI always; accurate recognition
of symptoms indicating onset of an anaphylaxis; timely
response to these symptoms; and, accurate administra-
tion of adrenaline using an AAI. Effective training
packages for anaphylaxis patients and their carers to
understand and address AAI behaviours are vital for
management of this long‐term condition.20-22
Anaphylaxis patients are typically seen in a range of
clinical settings and are routinely in contact with profes-
sionals from multiple disciplines including medical doctors,
nurses, and pharmacists.13,18 Where clinicians provide
patient education on AAI use, this has usually been
information focused and comprised of practical information
and device instructions.23,24 Information focused training is
necessary but found to be insufficient for effective patient
education25-27 and recent guidelines from the European
Academy of Allergy and Clinical Immunology describe
current approaches to AAI instruction as ineffective for
promoting patient AAI adherence.13 Around three‐quarters
of clinicians who train patients in AAI use cannot
demonstrate the correct technique18 and clinicians more
broadly do not know how to use AAIs correctly.5,28,29
Research suggests barriers to AAI use are not solely practical
but incorporate complex psychological features. Patients
and clinicians report treatment‐related, psychological, and
organisational barriers to AAI adherence.11,30-33 A diagnosis
of anaphylaxis can have psychosocial consequences that act
as barriers to self‐care behaviours, including effective use of
AAIs.22 Patients do not routinely update their AAI
prescription,34 and their carriage and use of AAIs is often
poor.35-39 Evidence also shows that less than 30% of patients
carry their AAI at all times.4 Only one‐third to half of
patients with anaphylaxis demonstrate the correct use
of their AAI, and only 44% report being able to use their
AAI correctly.4
Specialist allergy staff report feeling ill‐equipped to
manage the psychological factors associated with AAI
adherence among patients with anaphylaxis, highlighting
reasons such as time pressures, limited clinic space, and
lack of confidence.33 Anaphylaxis self‐management plans
have also been found to vary in quality and clinician‐
uptake.40-42 Evidence from paediatric settings has found
that staff led AAI training for parents and children can be
effective in increasing adherence when it considers
complex psychosocial factors which may be barriers to
self‐care behaviours, such as the attitudes of family
members and carers to anaphylaxis and AAI use, and
patients risk perceptions.36,43
Behavioural science theories can improve the design
of behaviour change interventions.44 Theories derived
from health psychology could be used to inform AAI
training for patients with anaphylaxis to address psycho-
logical barriers to AAI adherence. “Training the trainers”
of patients, namely clinicians, in psychologically in-
formed strategies for exploring and responding to these
barriers with patients could improve clinician delivered
training.45-48
This study examined the impact of a psychologically
informed workshop designed to improve staff knowledge
about psychological barriers to AAI use in patients with
anaphylaxis, as well as staff confidence and reported
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likelihood of using the strategies and techniques taught
in their practice.
2 | METHODS
2.1 | Design
A mixed‐methods design with a pre‐post questionnaire
was used to evaluate the impact of the workshop on
participants’ knowledge (of psychological strategies and
AAI adherence), confidence (to implemnt strategies), use
of strategies and techniques in practice, and organisa-
tional barriers to their implementation. Participants
completed an online 10‐item forced choice questionnaire
before, 1 to 3 and 6 to 8 weeks after attending a workshop
(see Table 2 for items).
Qualitative data were collected from attendees in one
to one telephone interviews 8 to 10 weeks following the
workshop, to provide more in‐depth evaluation of the
workshop impact and barriers to implementing the
strategies and techniques taught.
2.2 | Participants
Participant inclusion criteria were:
• They must be a practicing health care professional
working in general practice/community health care or
hospital‐based service;
• Their clinical role must include prescribing and/or
training adults, children or adolescents who have had
an anaphylaxis, or their adult carers, to use AAIs.
Clinicians working with patients with anaphylaxis in
emergency departments, specialist allergy services, and
general/community practice were sampled purposively to
ensure workshops groups were multiprofessional. The
workshop was delivered on four separate occasions and
29 clinicians attended in total (see Table 1).
Workshop attendees were mostly female (female: N=22,
85%; male: N=4, 15%, χ2 = 12.50, df=1, P< .001). The
majority attending were nurses (N=16, 61.5%) followed by
medical doctors (N=7, 27%) and pharmacy staff (N=3,
11.5%), respectively (χ2 = 9.00, df=2, P= .01). All medical
attendees worked in general practice/community health care
and all pharmacy clinicians worked in hospital‐based
services. Most nurse attendees (N=10, 62%) worked in
general practice/community health care, three (19%) in
hospital based paediatric services and three (19%) in hospital
emergency departments. Most attendees had no specialist
allergy training (no training: N=19, 73%; specialist allergy
training: N=7, 27%; χ2 = 5.60, df=1, P= .02).
2.3 | Materials
2.3.1 | Workshop
The workshop was designed to encourage clinicians to use
strategies and techniques taught to ask patients about
barriers to carrying and using AAIs; and to respond to these
using established behaviour change techniques when train-
ing patients with anaphylaxis to use AAIs. The workshop
was developed using key principles from Intervention
Mapping.49-56
The 90‐minute training workshop comprised of
four parts:
(1) an overview of adherence and why it needs to
improve for effective AAI use;
(2) an overview of barriers and facilitators to behaviour
change;
(3) theory‐based AAI training using behaviour change
techniques to respond to patients’ psychological
barriers to AAI adherence;
(4) a group‐based application of the behaviour change
strategies and techniques taught using two case studies,
followed by reflection on how the strategies taught could
be applied within attendees’ clinical practice.
Details of how the workshop was developed can be found
elsewhere.57 Two documents were produced to support
workshop attendees ongoing application of the training in
TABLE 1 Workshop attendees’ demographic and professional
characteristicsa
Characteristics
Sex N= 22 (85%)
Females N = 4 (15%)
Males
Age, y (N = 23)
Range 25‐58
Mean (SD) 40 (11)
Profession
Medicine 7 (27%)
Nursing 16 (61.5%)
Pharmacy 3 (11.5%)
Years supporting anaphylaxis patients
Range 0‐30
Mean (SD) 7 (8)
Specialist allergy training
Yes 7 (27%)
No 19 (73%)
Workshop sites
General practice 2
Hospital education centre 2
aData were collected with the online evaluation questionnaire completed
before attending the workshop. Although 29 clinicians attended workshops
only 26 completed the online evaluation questionnaire before attending that
captured these data.
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practice: the Anaphylaxis Management Plan and the AAI
Training Checklist. The Checklist describes specific behaviour
change techniques (BCTs) clinicians can use when commu-
nicating with patients about how they can identify the onset
of an anaphylaxis episode, carry and use AAIs effectively and
engage in more general self‐management behaviours
(eg, AAI prescription renewal and device storage). It is
designed to be used as an aide memoire for clinicians during
health encounters with patients at risk of anaphylaxis (see
Appendix for workshop documents).
TABLE 2 Number (%) of responses to the online evaluation before, 1 to 3 and 6 to 8 weeks after the workshop and χ2 analysis results
Before 1‐3 wk after 6‐8 wk after
How would you rate your knowledge of ways to facilitate AAI adherence with patients?
Very limited/don’t know 15 (58) 2 (8.5) 1 (8)a
Satisfactory/fairly good 9 (34) 8 (33.5) 4 (31)
Good/very good 2 (8) 14 (58) 8 (61)
χ2(df) 9.8 (2)** 8 (2)** 6.2 (1)**
How confident are you in your ability to facilitate AAI adherence in patients?
Not at all/a little 20 (77) 7 (29) 4 (31)
Moderately/confident/very 6 (23) 17 (71) 9 (69)
χ2(df) 7.5 (1)** 4.2 (1)* 1.90 (1) NS
How frequently do you use strategies to facilitate patients’ adherence to AAI Guidance?
Never/not very often/don’t know 20 (77) 15 (62.5) 9 (69)
Sometimes/most/all the time 6 (23) 9 (37.5) 4 (31)
χ2(df) 7.5 (1)** 1 (1) NS 1 (1) NS
How frequently do you use techniques to improve AAI adherence generally in patients?
Never/very rarely/rarely 22 (85) 14 (58) 7 (54)
Occasionally 3 (11) 7 (29) 0 (0)b
Frequent/very/always 1 (4) 3 (13) 6 (46)
χ2(df) 31 (2)* 7.8 (2)* 1 (1) NS
Do you intend using strategies to facilitate patient adherence to AAI Guidance in the future?
Yes 17 (65) 21 (87.5) 11 (85)
No/don’t know 9 (35) 3 (11.5) 2 (15)
χ2(df) 2.5 (1) NS 13.5 (1)** 6.2 (1)**
Currently, do any issues concern you when dealing with anaphylaxis patients?
Yes 13 (50) 3 (11.5) 1 (8)
No/don’t know 13 (50) 21 (87.5) 12 (92)
χ2(df) 0 (1) NS 13.5 (1)** 9.5 (1)**
Do you believe it is possible to bring about changes in patients adherence to AAI guidance?
None/small number/around half/don’t know 16 (61.5) 12 (50) 6 (46)
Most/all 10 (38.5) 12 (50) 7 (54)
χ2(df) 1.4 (1) NS 0 (1) NS 1 (1) NS
How important is promoting patient adherence to your role as a clinician?
Not at all/a little/don’t know 6 (23) 4 (17) 0 (0)b
Moderately/mostly 5 (19) 5 (21) 4 (31)
Very 15 (58) 15 (62) 9 (69)
χ2(df) 7 (2)* 9.3 (2)** 1.9(2)
Does your work environment enable you to promote patients adherence to AAI Guidance?
Not at all/a little/don’t know 14 (54) 10 (42) 4 (31)
Moderately 10 (38) 8 (33) 0 (0)b
Mostly/completely 2 (8) 6 (25) 9 (69)
χ2(df) 8.7 (2)** 1 (2) NS 1.9 (1) NS
Do you have access to resources that could facilitate patients’ adherence to AAI Guidance?
Yes 6 (23) 18 (75) 10 (77)
No/don’t know 20 (77) 6 (25) 3 (23)
χ2(df) 7.6 (1)** 6 (1)** 4 (1)*
Abbreviations: df, degree of freedom; NS, not significant.
aDue to small cell sizes the χ2 test of Goodness of Fit compared very limited/satisfactory (N = 2) and fairly good/good/very good (N = 11) against expected equal
cells sizes reducing df to 1.
bχ2 Test of Goodness of Fit only compared cells containing frequencies against expected equal cell sizes, thus reducing this analysis df to 1.
*P< .05.
**P< .01.
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2.4 | Procedure
Flyers were distributed at staff meetings to advertise the
workshops to eligible clinicians. Interested clinicians were
asked to contact the research team for further information.
Participants were emailed 1 week before their scheduled
workshop, and 1 to 3 and 6 to 8 weeks after attending with
a link to the online evaluation questionnaire. Postwork-
shop emails also invited attendees to contact the research
team to arrange a telephone interview in which the
workshop impact would be explored further.
2.5 | Ethics
Ethical approval was granted by the relevant higher
education institution, and organisational permission was
granted by the relevant National Health Service (NHS)
organisation.
3 | RESULTS
3.1 | Quantitative evaluation
Ninety percent (N = 26) of the 29 attendees at the four
workshops completed the evaluation before attending,
dropping to 83% (N= 24; nonresponders: 1 medicine and
1 nursing) at 1 to 3 weeks and 45% (N = 13; nonrespon-
ders: 4 medicine and 7 nursing) at 6 to 8 weeks after the
workshop. This overall response rate to the online
quantitative evaluation is similar to that found in online
surveys of clinicians.58-60
There was no significant difference between the mean
age of participants who only completed the online
questionnaire before attending the workshop (mean = 40
years, SD = 11) and those who completed the online
questionnaire before and on at least one other occasion
after attending (mean = 40, SD = 11) (t(22) = 0.03,
P= .90). Likewise, there was no significant difference
between the number of males and females in these two
groups (χ2 with Fisher’s exact correction = 1.30, df= 1,
P= .30), although every participant who completed the
online questionnaire at all three time points was female.
Most participants who completed the online question-
naire before and on at least one other occasion after
attending the workshop were nurses (68%, N = 13;
medical general practitioners 13%, N = 3; pharmacists
13%, N = 3). Among those who only completed the online
questionnaire before attending the workshop, the major-
ity were also nurses (57%, N = 4) and the remainder
medical General Practitioners (43%, N = 3).
The quantitative evaluation data were analysed in two
ways. Descriptive statistics were produced using χ2 Tests of
Goodness of Fit against expected equal cell sizes (P= .05
level). These provide evidence of the overall pattern of
clinicians’ self‐reported knowledge, confidence, and inten-
tion to use the strategies and techniques taught at each
assessment point independent of one another. Analysis of
paired responses used McNemar’s test that compares
binary dependent measures at two assessment points
and Cochran’s Q test that compares binary dependent
measures at three assessment points. Binary dependent
measures were produced by combining the response
options for each question with positive or negative
meaning (eg, knowledge self‐rated as satisfactory, fairly
good, good, and very good were treated as positive, and very
limited and don’t know were treated as negative). The
McNemar test and Cochran Q Test analyses provide
evidence of whether clinicians’ self‐reported knowledge,
confidence and intention to use the strategies and
techniques taught changed positively (improved) across
assessment points.
3.2 | Descriptive statistics
Response frequencies before and at 1 to 3 and 6 to 8
weeks after the workshop were analysed independently
using χ2 test of Goodness of Fit against expected equal
cell sizes (P= .05 level). Where cells sizes were small (<5)
response categories with similar meaning were combined
(eg, very good and good) to enable inferential statistical
analysis. Table 2 shows the number (%) of combined
responses, and χ2 test results.
Before the workshop 58% of attendees reported having
very limited knowledge about how to facilitate patient
AAI adherence. At 1 to 3 and 6 to 8 weeks Postworkshop
their self‐reported knowledge had improved, and 58%
and 61% respectively now rated their knowledge as good/
very good. Postworkshop findings also suggest clinician’s
self‐rated confidence in facilitating patients’ AAI adher-
ence improved from no/little confidence (preworkshop) to
moderately/very confident 1 to 3 and 6 to 8 weeks
postworkshop. Participants’ intention to use the strate-
gies and techniques taught to encourage adherence
showed sustained improvement in the postworkshop
findings, and fewer attendees reported concern about
dealing with patients with anaphylaxis (around 10%), a
significant change from high rates of concern (50%)
preworkshop. However, the number of participants who
felt it possible to affect change in anaphylaxis patients’
adherence to AAI guidance showed no significant pre‐
post change (pre: 38%; 1‐3 weeks postworkshop 50%; 6‐8
weeks postworkshop 54%). Nevertheless, the percentage
of attendees who believed their work environment
enabled them to facilitate their patients’ AAI adherence
increased following the workshop.
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3.3 | Analysis of paired responses
A series of 2 × 2 McNemar tests (with 0.5 Yates
Correction for small cell sizes) were run to compare
clinicians’ responses (N = 17) before and 1 to 3 weeks
after attending the workshop, and to compare their
responses 1 to 3 weeks and 6 to 8 weeks after
attending (N = 7). The results showed that at 1 to 3
weeks after compared to before attending the work-
shop, significantly more clinicians reported that their
knowledge about how to facilitate patient AAI
adherence (8, df = 2, P = .05) and their confidence to
do so (210, df = 2, P = .002) had improved. Also,
compared to before the workshop, at 1 to 3 weeks
after attending more clinicians reported that they
were using techniques frequently to encourage
patients AAI adherence (3.80, df = 2, P = .05) and that
they had access to resources that could facilitate this
(8, df = 2, P = .005). However, there was no change in
clinicians’ self‐reported frequency of using strategies
(1.12, df = 2, P = .30) or their intention to use them
(1.12, df = 2, P = .30). Likewise, compared to before
the workshop, at 1 to 3 weeks after attending there
were no significant changes clinicians’ concerns about
working with patients with anaphylaxis (3, df = 2,
P = .08) or their belief that they could change
patients AAI adherence (0.04, df = 2, P = .90). The
importance of promoting adherence to attendees’
clinical role (0.05, df = 2, P = .80) and how much they
believed their work environment enabled them to
facilitate patients’ adherence (0.10, df = 2, P = .80)
also remained unchanged across these two assessment
points. Comparisons made between clinicians’
responses 1 to 3 weeks and 6 to 8 weeks
after attending the workshop were not statistically
significant (P > .05). This suggests that across the two
postworkshop assessment points there were neither
significant improvements nor deteriorations in
clinicians’ self‐reported knowledge, confidence or
intention to use the strategies and techniques taught.
A series of 2 × 3 Cochran Q tests were run to
compare clinicians’ responses (N = 7) before, 1 to 3 and
6 to 8 weeks after attending the workshop. The results
show that those clinicians who completed all three
online evaluations reported improved knowledge of
ways to facilitate patients’ AAI adherence (Q = 6,
df= 2, P = .05) and improved confidence in their ability
to do so (Q = 8, df = 2, P = .02). They also reported
greater frequency of using strategies and techniques to
facilitate patients’ AAI adherence (Q = 6, df = 2,
P = 0.05; Q= 6.5, df= 2, P = .04), and that they had
access to resources that could facilitate patients AAI
adherence (Q = 7, df= 2, P = .03).
3.4 | Qualitative evaluation
All clinical groups attending the workshop were
represented in the interviewee sample (see Table 3).
Nine interviews were conducted in total (31% of the
workshop participant group). Interview duration
ranged from 10 to 30 minutes, each digitally audio
recorded, transcribed verbatim and anonymised. The-
matic analysis (TA) was used to explore interview
data.61 Themes represent distinct patterns in the data,
comprised of smaller information extracts or codes.
Codes were identified and collated into themes using
a priori interest in the impact of the workshop on
attendees and their perceptions of barriers and
facilitators to encouraging anaphylaxis patients’ AAI
adherence. Five themes emerged from the codes and
these are shown Table 4. The analytic procedure was
as follows: working independently, two members of
the research team (BM and EW) familiarised them-
selves with the transcripts, annotating potential codes.
Each then analysed the data line‐by‐line to identify
codes that enhanced understanding of the a priori
issues. Working collectively, BM and EW then
collated their codes with similar meaning and then
grouped these into themes (see Table 4).
3.5 | Impact of the workshop on
trainees
3.5.1 | Transformed clinician
knowledge, beliefs, and intention
Interviewees described how they now understood
patients’ experiences of anaphylaxis were psychological,
not purely physical:
“I didn’t appreciate what complications they
might have after leaving us… emotions they might
go through… it’s given me… a broader knowledge
of what they might be going through after they’ve
had this event.”
(Emergency Department nurse 1)
Interviewees prior expectations of patients and their
adherence were challenged by the workshops and
interviewees felt their awareness of adherence behaviour
was enhanced. They now understood they should:
“Not just presume because somebody needs
something that they’re actually going to use it”
(Emergency Department nurse 2)
The workshop heightened interviewees’ awareness of
their own role in communicating with patients and the
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importance of this communication for subsequent patient
AAI adherence:
“I didn’t realise what the follow‐up and the
implications of what we do are.”
(Emergency Department nurse 1)
Several interviewees described how this increased
awareness had encouraged them to be more thoughtful
about the language they used when sharing information:
“…the odd use of language… might have then
led on to a patient’s misinterpretation…”
(General Practitioner)
Some reported the workshop had stimulated a
fundamental change in their communication style when
working with anaphylaxis and other patient groups:
“…a completely different view of how to
approach patients now.”
(Pharmacist)
All described becoming sceptical about the effective-
ness of instructional information‐driven approaches
when training anaphylaxis patients to use AAIs:
TABLE 3 Interviewee professions
Characteristics N
Medicine
Medical general practitioner 1
Nursing
General practice nurse 1
Allergy service nurse 2
Emergency department nurse 3
Pharmacist 1
Other
Paediatric play therapist 1
TABLE 4 Interview a priori issues, themes and codes
“A Priori” Issue Theme Codes
Impact of the workshop on trainees Transformed clinician
knowledge, beliefs and intention
Understanding the care pathway
Raised awareness of patient barriers to adherence
Importance of practitioner‐patient communication
Salience of AAI adherence
Knowledge and beliefs about strategies
Intention to change practice
Changed clinician and
patient behaviour
Improved practitioner‐patient communication
strategies
Departmental discussions/disseminating practice
Reinforcement of existing practice
Mirroring staff changes
Patient feedback
Application of behaviour change techniques
Active listening
Practitioner experiences and resources
Perception of barriers and facilitators
to encouraging anaphylaxis patients
AAI adherence
Disjointed anaphylaxis
care pathway
Assumption making
Primary care new ways of working
Adult versus paediatric
Rare condition Clinicians
Patients
Importance of time Time as a barrier
Questioning time as a barrier
Time as a facilitator
Signposting
Abbreviation: AAI, adrenaline with an autoinjector.
220 | MAHONEY ET AL.
“(the workshop)… made me think more about
not just when you're speaking to people… it
isn’t just how this works and why you should
use it, but thinking about why this person
might not use it.…”
(Practice nurse)
The workshop also signalled the important role of all
practitioners in encouraging patient AAI adherence, as a
mechanism towards better self‐management
“We’re clinicians (but) it’s really neglectful to
give someone that kind of training and not
try to influence their behaviour and their
thinking, and help them help themselves.”
(Allergy Service nurse 1)
The multiprofessional composition of workshop
groups was an unexpected workshop benefit,
providing attendees new opportunities for multipro-
fessional discussion about alternative approaches,
referral points and to understand different elements
of the care pathway for patients with anaphylaxis.
Discussions in workshop groups revealed attendees’
erroneous beliefs about the practices of other
healthcare staff working specifically with adult
patients with anaphylaxis. Attendees based outside
specialist Allergy Services were unaware that,
depending on referral circumstances, adult patients
particularly may face a lengthy waiting time before
being seen within Services. Understanding more
about pathway rules and potential wait times encour-
aged attendees to reconsider the information patients
would need about their treatment and prevention of
future episodes of anaphylaxis:
“Knowing now, that they’re not seen for…
months we need to be giving them a bit more
time to come to terms with this, and explaining
it a little bit more”
(Emergency Department nurse 1)
Allergy service clinicians developed awareness of
other clinicians’ assumptions about adult anaphylaxis
patients’ care pathway and their own clinical practices
with patients:
“People think we do stuff we don’t do. We
don’t see them…”
(Allergy Service nurse 2)
Where participants had attended the workshops as
whole teams, aspirations were shared about the potential
to change the culture of patient communication and
information‐exchange:
“I think, because there were so many of us
which were trained at the same time as well,
so it now becomes a culture and a general
feeling among ourselves.”
(Emergency Department nurse 3)
3.5.2 | Changed clinician and patient
behaviour
Interviewees described how the workshop increased
their confidence and knowledge about exploring and
responding to psychological aspects of AAI adherence:
“…in terms of my behaviour, I feel… very
confident. Before the workshop I think I scored
low there… if I were to encounter these patients…
I would be pro‐promoting all of those things.”
(Emergency Department nurse 3)
Many described intending to use the strategies and
support documents to enhance different aspects of their
clinical practice. Emergency Department clinicians felt
the Anaphylaxis Management Plan in particular, would
help them make better use of the brief health encounters
they had with these patients:
“…none of that information was ever given to
patients. It might’ve been verbally said, but…
in the heat of A&E and when you’re busy, and
people have usually had the shock of their lives
they’re not taking it in… to give them some-
thing to go away with, to give them thoughts is
excellent…”
(Emergency Department nurse 1)
Changes in clinical practice supporting patients with
anaphylaxis had already been made by some clinicians:
“I think I’ve been more empathetic towards
them… when I see them in the hospital
and give them their pen, they’ve had the
reaction, and it’s either they’re first time…
all I’ve done is just bombarded them
with questions… now, thinking about it,
thinking, “Okay, some… need that support
afterwards.”
(Pharmacist)
Interviewees were optimistic that implementing the
techniques and strategies learnt would enhance their
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communication with patients and encourage self‐man-
agement behaviours:
“…make(s) them a bit more open to talking to
me and telling me things and just being that
little bit more open. “Actually, no, maybe I
don't take…” If I can be a bit more open… just
listening… that was a big thing as well.”
(Emergency Department nurse 2)
Interviewees felt more confident and knowledge-
able about how to encourage anaphylaxis patients AAI
adherence. Many believed training clinicians in
behaviour change and active listening techniques
would help them discuss risk and AAI adherence
with patients:
“I think with the anaphylaxis thing it’s more
sort of ‘it’s really important that you use this’
…without making people scared.”
(Emergency Department nurse 2)
Discussions with patients using the strategies and
techniques taught were described as having the potential
to empower patients, encouraging patient’s active in-
volvement in shared decision making with staff about
their self‐care behaviours:
“It’s giving them the tools, things that they
might not have thought of, that there might be
complications in carrying their EpiPen… It’s
giving them the tools to think about how
they’re going to get over those problems.”
(Emergency Department nurse 1)
“I think its… making them aware… their relatives
as well… that it’s not a disease burden, and it can
be prevented. All you need to do is just be
confident on using it… knowing where to go… and
have that confidence.”
(Pharmacist)
However, there was a perception that this could also
depend on clinicians having particular “experience” and
“skill.”
“…it’s more to do with experience… the more
experience I have in talking to patients in that
way, will help me develop myself to be a bit more
confident on approaching these patients.”
(Pharmacist)
3.6 | Perceptions of barriers and
facilitators to encouraging anaphylaxis
patients’ aai adherence
3.6.1 | Disjointed anaphylaxis care
pathway
Despite interviewees’ optimism about the benefits of
using the workshop strategies and techniques, all were
aware that anaphylaxis patients could dispense their
AAIs from a range of different professionals, and in a
range of clinical contexts. Heightened awareness of the
importance of communication led to enhanced fears
about whether all staff would spend time at administra-
tion as required:
“It relies on the nursing staff to counsel the
patients as well. Sometimes, when you’re just
so busy, and you get a script for an EpiPen,
you just say to the nurse, “Oh, it’s stocked on
your ward, so just you give it straight from the
cupboard”… Hand it over, and then you just
hope that they will either read the (instruc-
tions)… or the nurse will explain it to them”
(Pharmacist)
All staff were aware of time pressures and the barriers
these could place on effective information exchange:
“We see so many patients on… allergy morning
clinic… time spent with these patients is a
tiny percentage… you’re just there to show them
the technique, to… get across in five or ten
minutes how important it is. Then they’re on their
way, you never see them again, there’s no follow‐
up. We don’t know if any of them will end up
being readmitted.”
(Allergy Service nurse 1)
The workshop facilitated consideration about
potential improvements to the anaphylaxis care pathway.
Primary care settings were highlighted as providing
opportunities for this study:
“…in hospital, they don’t really know you. We
don’t have that relationship because they come
in and out. In primary care, they know their
doctors… their local community pharmacists,
community nurses”
(Pharmacist)
However, some participants felt organisational culture
could be a key barrier to any change:
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“…it’s working with people that don’t want
change… if the people in charge or the depart-
ment don’t want to make change… there’s
nothing I can do.”
(Allergy Service nurse 2)
3.6.2 | Rare condition
Infrequent encounters were perceived to be a barrier to
working consistently with patients to encourage AAI
adherence:
“It was a good reminder because we don’t
actually see very many people with it or deal
with it. We often see people with EpiPens but
people don’t have many attacks, do they? We
don’t have much anaphylaxis.”
(General Practitioner)
The clinical features of anaphylaxis were also felt to be
a barrier to AAI adherence:
“…it’s the patients themselves as well. If
someone had (not) an anaphylactic reaction
for years, they would just be… “Okay, that’s
not going to happen to me again…”… they
would not be interested. The ones that have
had quite a few, would be more interested, or
the ones that can remember the reaction, or
even relatives that have seen it happen would
be more aware and… “Oh, I don’t want that to
happen again”… patient themselves, if they
haven’t had it for a while, they won't be that
interested… they won't even tell me about their
EpiPens on their repeat scripts… they don’t
think it’s important… and “Oh, yes, I just use
that when I have a reaction,” that’s when I
find out more about it… they… don’t class it as
a medicine… as important for the doctors or
the pharmacy team to know.”
(Pharmacist)
For those patients with a first anaphylactic reaction in
adulthood, there were perceived to be additional psycho-
logical barriers to adherence:
“…it is very different when you’re a parent and
you’re anxious about… your child… parents…
say, “I just want to be sure I know how to do
this?” they probably want to run through it
several times… want a leaflet. Some of them
might call back… if you are an adult you’ve
still got that anxiety about giving it to
yourself… thinking, “What if I’m already
suffering the effects of allergy when I’ve got
to give it.”
(Paediatric Play therapist)
3.6.3 | Importance of time
All interviewees perceived time as a primary barrier
for them:
“…it’s time… the pressure and the stress of
working in that environment. If I’ve got loads
of stuff to do, it’d be more difficult to spend a
while talking to the patient. Time is precious
when you’re really stressed… short staffed…
getting bleeped everywhere”
(Pharmacist)
Allergy Service staff also described how time could be
a barrier in relation to other communication and
relationships. Many felt that patients needed more time
to feel comfortable describing their emotions and
thoughts about their anaphylaxis:
“It’s hard to build a professional rapport with
someone in that time where they might actually
say, “Well, to be honest with you, I'm scared to
my wits every time I hear a wasp or a bee.”
(Allergy Service nurse 1)
Some interviewees now believed that clinicians should
“make time” given the importance of AAI adherence:
“I feel… you just need to step back and be like,
“Okay, I need to make time”.
(Pharmacist)
A number of clinicians believed that invoking time
poverty as a barrier reflected organisational culture
rather being a real practical barrier:
“It is also, attitude… if you’re hardened to not
having time, it's’ going to then be very hard to
be open to it.”
(Paediatric Play Therapist)
Signposting anaphylaxis patients to other resources that
might encourage their AAI adherence was also believed to
be a strategy for using clinical time productively:
“Even if you do have ten minutes and…
struggling… that’s when… to signpost… say
‘I acknowledge that this might be an issue.
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This is where you can go if you want to find
out more.’… may be… there isn’t really some-
where else, but even if you’re just told “come
back again” or “you can call this helpline,”
something.”
(Paediatric Play Therapist)
4 | DISCUSSION
Evidence from paediatric settings shows staff led AAI
training that considers complex psychosocial factors
associated with self‐care behaviours can be more
effective for increasing AAI adherence. The findings
of the study reported are consistent with this
literature. The workshop improved attendees’ self‐
reported knowledge, confidence and likelihood of
using the strategies and techniques taught for
exploring and responding to patients’ psychological
barriers to AAI use. The mixed‐methods longitudinal
design suggests improvements were sustained.
To the best of our knowledge this is one of a small
number of published studies that has used Health
Psychology intervention mapping principles to
design a brief training intervention for clinicians in
psychologically ‐ informed strategies they can use
to encourage AAI adherence among adult patients
with anaphylaxis.
The quantitative findings are consistent with those
from studies that demonstrate training delivered
through a lecture plus practical activity workshop
format is effective for improving clinician AAI use;
and, to educate parents of children with anaphylaxis
in effective management of their child’s anaphy-
laxis.45-47 Clinicians self‐reported knowledge, confi-
dence and intention to use the strategies taught
improved after attending the workshop. Evidence
shows these are precursors to behaviour change52-55
and clinicians are more likely to engage in education
and treatment behaviours with patients if they feel
knowledgeable and confident about using the
behaviours and report an intention to apply them in
their practice.62-64 Evidence also shows that patients
with long‐term conditions have fewer emergency
department admissions if supported by clinicians
educated in communication strategies of the type
taught in the workshop that encourage discussion
with clinicians about self‐management concerns
and goals.65 Patients also prefer clinicians to incorpo-
rate the type of strategies and techniques taught
in the workshop in their communication with patients
(eg, open questions to encourage exploration of
self‐care barriers and identifying solutions through
shared decision making with clinicians). The strate-
gies and techniques taught in the workshop can also
facilitate clinicians use of patient‐led and focused
approaches to communication that are preferred by
individuals with long‐term conditions, such as
anaphylaxis.48 Additionally, the strategies and
techniques taught in the workshop are designed to
encourage patients to take an active role in their AAI
education, and patient education provided by clin-
icians is more effective when the patient takes this
role in the process.66,67
The workshop impact on how the clinicians
interacted with anaphylaxis and other patient groups
was an unexpected positive outcome. This shows
the workshop was also effective for altering clinicians’
approach to patient education more generally. This
new approach incorporated awareness that the
provision of information alone is insufficient for
facilitating patient’s self‐care.67
The workshop was less successful in increasing the
number of clinicians who believed they could affect
change in patients AAI adherence. Pessimism about a
behaviour or treatment strategy can be a barrier to its
implementation by clinicians.68 The qualitative data
suggest this pessimism was related to perceived organi-
sational, care‐pathway and time barriers that were
perceived to be beyond the control of participants
attending the training. The workshop content did not
consider these barriers; and, evidence shows clinicians
often cite these factors as barriers to implementing new
communication strategies with patients in their prac-
tice.68-71 The pessimism may, however, also reflect an
increased awareness of the complex psychological
features associated with anaphylaxis amongst workshop
participants. This highlights the importance of provid-
ing organisationally relevant signposting and referral
pathways for clinical staff who may want to refer
patients on for more complex psychological issues
associated with anaphylaxis. In planning future
workshops, it may be possible to include such informa-
tion alongside the checklist. In addition, participants
could be encouraged to form peer‐to‐peer communities
of practice as they implement new strategies in practice,
to feedback new ideas as well as unpick ongoing
organisational and professional challenges associated
with their contact with anaphylaxis patients. These
could be supported with virtual platforms or arranged
via a 6‐monthly workshop catch‐up group.
The study has several implications for clinical practice.
Health Psychology theory can support the development of
effective brief training packages to help clinicians to
effectively exchange information with patients living with
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potentially life‐threatening diseases which require patient‐
led management and control. A recommendation from this
study is that psychologically informed training, with
accompanying tools (eg, checklists) to promote information
exchange are available routinely to all clinicians who
manage patients with anaphylaxis. Brief, psychologically
informed training can be an effective way of supporting
staff to explore the range of barriers and facilitators related
to AAI adherence among patients with anaphylaxis. The
Management Plan and AAI Training Checklist, as developed
in this study, could be used to enhance patient AAI training
directly (eg, to structure the health encounter with a
patient) and indirectly (eg, as a training aide memoire for
clinicians before their health encounter with a patient).
This study suggests that clinicians who encounter
patients with anaphylaxis at all points of the care
pathway should not assume that clinicians other than
themselves will train these patients in AAI use. There
are some staff for whom training of this nature would
be particularly helpful. Staff working in emergency
departments may be the first point of contact during,
or following, an anaphylaxis emergency, so have an
important role to play in the provision of early
information about anaphylaxis, including prevention.
Specialist allergy staff also have an important role in
the provision of practical and psychological informa-
tion about the impact of anaphylaxis over the longer‐
term, particularly for those with adult‐onset. In terms
of longer‐term management of anaphylaxis, clinicians
based in primary care services have an ongoing role to
play in relation to the exploration, and response to,
any patient barriers to AAI adherence. For pharma-
cists, prescription renewal may provide a trigger for
effective information exchange about AAI use, in-
cluding the exploration of intentional and uninten-
tional nonadherence. Given the benefits from whole
team training, team workshops would provide new
opportunities to skill up staff knowledge and experi-
ence in this area, with a “train the trainer” approach
encouraging input from experienced colleagues who
could share their experiences of implementing new
techniques in practice. Reflections amongst collea-
gues with direct experience of utilising the workshops
tools should encourage discussion about the time
required for information exchange of this nature, to
help colleagues consider how to overcome any
anxieties about time poverty.
Although the study produced several promising
findings, there were some limitations to this study.
The sample was self‐selected. It was possible that the
clinicians who volunteered to attend the training did
so because they felt positively about the training
before attending the workshop. The sample size was
relatively small with some attrition over time. How-
ever, the attrition rate was not dissimilar to that found
in other studies with clinicians that have used online
data collection methods that are similar to that used
in the quantitative element of this study. The study
captured perceived impact on practice rather than
measuring any actual changes to behaviour in
practice. Future studies would benefit from evaluating
actual changes to clinical practice in identified
practice areas. In addition, the impact of training on
the exchanges between clinicians and patients would
be a helpful focus for future research and could
inform further developments to the training workshop
materials.
5 | CONCLUSION
Findings from this study suggest that a psychologi-
cally informed training workshop for clinicians, with
accompanying tools for practice, increases clinician
awareness about the psychological consequences of
anaphylaxis. Further research is needed to understand
more about patient behaviours (intentional and
unintentional) which reduce the likelihood of AAI
adherence amongst adults, for targeting through
training to encourage effective patient and staff
information exchange.
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